HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)--EURObservational Research Program of the European Society of Cardiology.

Abstract
The goal of adjuvant anti-cancer therapies is cure with limited or no side effects, in particular long-term side effects with negative impact on quality of life. In the palliative setting disease control, quality of life and overall survival are important end points. Partly due to improvements in treatment, the population of cancer survivors is large and growing. However, anti-cancer drug-related cardiotoxicity (ADRC) is the leading cause of treatment-associated mortality in cancer survivors. It is one of the most common post-treatment problems among 5- to 10-year survivors of adult cancer. This is particularly true for breast cancer, the most common cancer in women. The EACVI/HFA COT registry is designed for comprehensive data collection and evaluation of the current European practice in terms of diagnosis and management of ADRC in breast cancer patients. The COT registry will be carried out in two continuing phases, the pilot study phase involving 13 countries followed by the long-term registry in which all the 56 ESC countries will be invited to participate. With the COT registry, several critical information will be obtained: on predisposing factors for the development of ADRC, the rate of subclinical LV dysfunction and its transition to overt heart failure, the clinical impact and outcome of ADRC.
AuthorsPatrizio Lancellotti, Stefan D Anker, Erwan Donal, Thor Edvardsen, Bogdan A Popescu, Dimitrios Farmakis, Gerasimos Filippatos, Gilbert Habib, Aldo P Maggioni, Guy Jerusalem, Maurizio Galderisi
JournalEuropean heart journal. Cardiovascular Imaging (Eur Heart J Cardiovasc Imaging) Vol. 16 Issue 5 Pg. 466-70 (May 2015) ISSN: 2047-2412 [Electronic] England
PMID25744342 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, Review)
CopyrightPublished on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: [email protected].
Chemical References
  • Antineoplastic Agents
  • Cardiotoxins
Topics
  • Antineoplastic Agents (adverse effects)
  • Breast Neoplasms (drug therapy)
  • Cardiotoxicity (epidemiology, etiology)
  • Cardiotoxins (adverse effects)
  • Drug Interactions
  • Europe (epidemiology)
  • Female
  • Humans
  • Prospective Studies
  • Quality of Life
  • Registries
  • Research Design
  • Risk Factors
  • Societies, Medical

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: